2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6154 Independent cost-effectiveness analysis of second-line T-cell engaging therapies for multiple myeloma: Ciltacabtagene autoleucel vs teclistamab ± daratumumab vs standard-of-care

Edward R. Scheffer Cliff, MD, MPH, Shonali Midha, MD2, Mark Soliman, MS3, Nicholas Groblewski, BS4, Gregory A. Abel, MD, MPH5, Corey Cutler, MD,FRCPC,MPH6, Omar Nadeem, MD7, Amar Harry Kelkar, MD, MPH8
1 Brigham & Women's Hospital, Boston, Massachusetts, United States, Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Background: Therapeutic advances have more than doubled median overall survival (OS) in multiple myeloma (MM) over the past two decades, yet most randomized trials improved only progression-free survival (PFS). B cell maturation antigen (BCMA)-targeting therapies are likely to improve OS further: in the randomized CARTITUDE-4 trial, the BCMA-targeting chimeric antigen receptor T cell (CAR T) therapy ciltacabtagene autoleucel (cilta-cel) improved PFS and OS versus standard of care (SOC) treatment (San-Miguel 2023; Einsele 2026). The anti-BCMA bispecific antibody (BsAb) teclistamab, as a single agent (MajesTEC-9; Touzeau 2026) or with daratumumab (MajesTEC-3; Costa 2026), likewise significantly improved PFS and OS. While there appears to be clinical equipoise between these BCMA-directed immunotherapies, the three trials enrolled distinct populations and no head-to-head trial exists. Notably, the BsAb trials enrolled older and potentially sicker cohorts than CARTITUDE-4, which required patients fit enough for lymphodepleting chemotherapy and disease kinetics permitting CAR T manufacture. Choice of second-line MM therapy is a highly consequential decision, both clinically and from a cost perspective, as each treatment strategy can potentially exceed $500,000 per patient.

Methods: In this independent, academic cost-effectiveness analysis, we built a state-transition microsimulation model of lenalidomide-refractory MM with one prior line of therapy, following a prespecified treatment algorithm from second (2L) through fourth line (4L) over a 10-year horizon from the US healthcare sector perspective, using previously validated methods (Kelkar Annals of Internal Medicine 2023). Patients occupied three, monthly-cycle health states: PFS, progressive disease, and death (absorbing state). Three 2L strategies were compared: SOC (87% daratumumab-pomalidomide-dexamethasone, 13% pomalidomide-bortezomib-dexamethasone, per CARTITUDE-4); cilta-cel; and BsAb (teclistamab-daratumumab in the 74% daratumumab-naïve; teclistamab alone in the 26% daratumumab-exposed; matching CARTITUDE-4 CD38 exposure). Additional outcomes data were derived from CANDOR (daratumumab-carfilzomib-dexamethasone; Usmani 2021, 2023), carfilzomib-pomalidomide-dexamethasone (Bringhen 2018), and MonumenTAL-1 (talquetamab; Chari 2022, 2025). Back-to-back treatment with an alternate BCMA-directed therapy required progression to occur ≥9 months after prior BCMA therapy. Talquetamab was restricted to 4L due to tolerability. Kaplan-Meier OS and PFS curves were digitized and extrapolated by fitting a Weibull parametric model to observed time-to-event data, enabling predictions beyond trial follow-up. Health state utility values were derived from CARTITUDE-4 PROs (Mina 2025) and Hatswell et al (2019). Costs were derived from Veterans Affairs Federal Supply Schedule drug prices and Medicare procedure costs in 2026 US dollars. Costs and quality-adjusted life-years (QALYs) were discounted 3%/year. In the base case analysis, we simulated 10,000 patients per strategy.

Results: Median OS was 49 months with SOC, 103 months with cilta-cel, and not reached with BsAb; median PFS was 13 months, 50 months, and not reached, respectively. Mean effectiveness was 3.06 QALYs with SOC, 4.07 with cilta-cel, and 4.37 with BsAb, at mean lifetime costs of $1,556,445, $999,536, and $333,411. Cilta-cel thus dominated SOC, and BsAb dominated both cilta-cel and SOC, yielding more QALYs at lower cost; incremental cost-effectiveness ratios were therefore negative and not interpretable. At a societal willingness-to-pay (WTP) threshold of $150,000/QALY, net monetary benefit (NMB) was -$1,097,062 for SOC, -$389,467 for cilta-cel, and $322,529 for BsAb. Incremental NMB was $707,595 for cilta-cel versus SOC, $1,419,591 for BsAb versus SOC, and $711,996 for BsAb versus cilta-cel.

Conclusions: At first relapse, BsAb was cost-effective compared with both cilta-cel and SOC, and cilta-cel was cost-effective compared with SOC. Indeed, teclistamab ± daratumumab dominated both comparators and cilta-cel dominated SOC, so these findings hold at any WTP threshold. Notably, our base case analysis modeled continuous-duration teclistamab, whereas a scenario analysis of fixed-duration therapy was even more cost-effective, reinforcing a case for fixed-duration and de-escalation trials. Absent a head-to-head trial, these findings should inform coverage policy, guideline development, and shared decision-making.

Amar Harry Kelkar, MD, MPH: American Medical Association - Current Employment